Author

Joachim Kiefer

Observed name: Kiefer, Joachim

Institution: Gedeon Richter (Hungary)

Observed institution: Gedeon Richter (Hungary)

ORCID: 0000-0002-3990-0917

Observed ORCID: 0000-0002-3990-0917

OpenAlex ID: A5072045920

Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration

2021 · Frank G. Holz, Piotr Oleksy, et al. · Ophthalmology · 75

Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phase

2026 · Serge Ferrari, Lothar Seefried, et al. · Osteoporosis International · 1

A Randomized Phase 1 Study Comparing the PK , PD , Safety, and Immunogenicity of Proposed Biosimilar RGB ‐14‐X and Denosumab in Healthy Adult Males

2026 · Emmanuel Biver, Jean‐Jacques Body, et al. · Clinical and Translational Science · 1

Corrigendum to ‘Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study’ [EULAR Rheumatology Open 1 (2025) 282–290]

2026 · Tomoko Hasunuma, Paul Emery, et al. · EULAR Rheumatology Open

Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised study

2026 · Hiroaki Matsuno, Ernest Choy, et al. · EULAR Rheumatology Open

Clinical development programme of RGB-19 as a biosimilar to tocilizumab

2026 · Ernest Choy, Gordana Dancer, et al. · Video Journal of Biomedicine

Implementation of DVGW Guideline W 1001 at a RheinEnergie Waterworks (Cologne)

2014 · Sturm, Sebastian, Kiefer, Joachim, et al. · gwf - Wasser|Abwasser

Works count: 8

Citation count: 78

H-index: 1

I10-index: 1